A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants

J Clin Gastroenterol. May-Jun 2005;39(5):385-9. doi: 10.1097/01.mcg.0000159217.47419.5b.

Abstract

Goals: This clinical trial was carried out to determine whether oral treatment with a commercial probiotic formula containing Bifidobacterium lactis and Streptococcus thermophilus would reduce the frequency of antibiotic-associated diarrhea (AAD) in infants.

Study: In this double-bind formula controlled study, 80 infants, 6 to 36 months of age, were randomly assigned to receive a commercial formula containing 10 viable cells of B. lactis and 10 viable cells of S. thermophilus at the initiation of antibiotics for a duration of 15 days. The infants were assessed daily for formula intake, stool frequency, and stool consistency for a total duration of 30 days. Seventy-seven infants received nonsupplemented formula for the entire duration.

Results: There was a significant difference in the incidence of AAD in the children receiving probiotic-supplemented formula (16%) than nonsupplemented formula (31%).

Conclusions: The present study shows that prevention against AAD in infants was obtained by oral treatment with daily dose of B. lactis and S. thermophilus.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Anti-Bacterial Agents / adverse effects*
  • Bifidobacterium*
  • Diarrhea / chemically induced
  • Diarrhea / prevention & control*
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • Humans
  • Infant
  • Infections / drug therapy
  • Male
  • Probiotics / administration & dosage
  • Probiotics / therapeutic use*
  • Streptococcus thermophilus*
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents